Analyst firms · UBS · PFE
UBS PFE price target and rating history
Pfizer Inc. (PFE) · Health Care
UBS rates Pfizer Inc. (PFE) Neutral with a $25 price target, as of its latest action on Jan 7, 2026. It has published 4 rating actions on PFE since December 2021, including 1 upgrade and 1 downgrade. Across 8 firms with a PFE price target in the last 12 months, the median target is $26.50. UBS's $25 is 6% below that.
- Current rating
- Neutral
- Price target
- $25
- Median target, all firms
- $26.50
- Actions on PFE
- 4
UBS price target on PFE
Every UBS rating on PFE
- Jan 7, 2026
- Oct 20, 2023
- Jan 26, 2023
- Dec 13, 2021
How other firms rate PFE
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| DZ Bank | Hold | Nov 6, 2026 | |
| HSBC | Hold | $28 | Jul 6, 2026 |
| RBC Capital Markets | Sector Perform | $25 | Jun 10, 2026 |
| Argus Research | Buy | $35 | Mar 2, 2026 |
| Barclays | Underweight | $25 | Feb 20, 2026 |
| Daiwa | Neutral | $27 | Feb 12, 2026 |
| UBS | Neutral | $25 | Jan 7, 2026 |
| Citigroup | Neutral | $26 | Dec 2, 2025 |
| Scotiabank | Sector Outperform | $30 | Nov 13, 2025 |
Questions about UBS and PFE
- What is UBS's price target for PFE?
- UBS's latest stated price target for Pfizer Inc. (PFE) is $25, from its action on Jan 7, 2026.
- What is UBS's rating on PFE?
- UBS rates PFE Neutral, a neutral rating, as of Jan 7, 2026.
- When did UBS last change its view on PFE?
- On Jan 7, 2026, UBS resumes coverage at Neutral, price target $25.
- How does UBS's PFE target compare with other analysts?
- Across 8 firms with a PFE price target in the last 12 months, the median target is $26.50. UBS's $25 is 6% below that.
More PFE rating histories
All UBS ratingsPFE news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.